Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune efficacy
Show results for
Products

Companies

News
Articles
Videos

Refine by
Date

  • Older

Immune Efficacy Articles & Analysis

17 news found

Advanced Tumor Organoid & CAF Co-culture Service to Accelerate Cancer Research

Advanced Tumor Organoid & CAF Co-culture Service to Accelerate Cancer Research

Recent studies have also revealed CAFs' crucial role in modulating the immune system. Targeting intervention by altering CAF numbers, subtypes or functional characteristics is emerging as a novel approach to enhancing the efficacy of cancer treatment. ...

ByCD Bioparticles


Influenza A Virus Mouse Models for Accelerated Research

Influenza A Virus Mouse Models for Accelerated Research

These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...

ByCreative Diagnostics


Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...

ByGreenwich LifeSciences, Inc.


Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...

ByGreenwich LifeSciences, Inc.


Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. ...

ByAffimed GmbH


Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

In a completed randomized, single-blinded, placebo-controlled, multi-center Phase IIb clinical trial led by MD Anderson Cancer Center, no recurrences were observed in patients treated with GLSI-100 in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 months, which is the time required to reach ...

ByGreenwich LifeSciences, Inc.


Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

We are planning to study the peak immunity of GP2 and how to assess when to administer booster injections. ...

ByGreenwich LifeSciences, Inc.


First patient enrolled in Diamyd Medical`s Phase III trial Diagnode-3

First patient enrolled in Diamyd Medical`s Phase III trial Diagnode-3

The trial will evaluate the safety, the impact on the immune system and the clinical efficacy of an additional injection with the antigen-specific immunotherapy Diamyd®. ...

ByDiamyd Medical AB


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Phase 1 clinical trial of IO-108 in solid tumors. Immune-Onc plans to evaluate the efficacy, safety, and tolerability of IO-108 in combination with pembrolizumab in indication-specific expansion cohorts in China. ...

ByImmune-Onc Therapeutics, Inc.


Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron

Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron

Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including ...

ByAtriva Therapeutics GmbH


City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer

City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer

Last summer, City of Hope granted an exclusive worldwide license to Osel for intellectual property on the novel use of CBM588 to enhance the efficacy of checkpoint inhibitors to treat cancer. In the clinical trial, 30 patients with metastatic kidney cancer (renal cell carcinoma) who had never received treatment before were randomized to receive either CBM588 orally in ...

ByOsel Inc.


Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

“We are pleased to initiate OBERTO 201, a Phase 1b trial designed to evaluate the efficacy of PolyPEPI1018 in late-stage MSS mCRC, a patient population with a poor prognosis and few available therapies,” said Dr. ...

ByTreos Bio Limited


City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications

City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications

City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...

ByOsel Inc.


Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma

Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma

“There is considerable interest in microbiome modulation to enhance immune checkpoint inhibitor efficacy that is more consistent and scalable than fecal transplants. ...

ByOsel Inc.


AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. While the advent of these inhibitors has brought significant benefit to patients with cancer, ...

ByExscientia


MV BioTherapeutics to present at 5th Microbiome Movement - Drug Development Europe

MV BioTherapeutics to present at 5th Microbiome Movement - Drug Development Europe

Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal immunity by inhibition of eATP signalling Enhancement of immune checkpoint blockade by eATP interfering biotherapeutics “We were ...

ByMV BioTherapeutics SA


AKCP Develops COVID-19 Vaccine Delivery Monitoring

AKCP Develops COVID-19 Vaccine Delivery Monitoring

With so much at stake in terms of cost of vaccines and the efficacy of the immunization, AKCP has developed a complete end to end monitoring solution. ...

ByAKCP

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT